NOVEL SMALL MOLECULE COMPOUND INHIBITING SIGNAL TRANSMISSION PATH OF TLR7 AND TLR9 AND USE THEREOF

The present invention relates to a small molecule compound inhibiting a toll-like receptor (TLR) signal transmission path and, more specifically, to a compound having a structure expressed by a particular chemical formula, a TLR inhibitory composition comprising same, and an autoimmune disease or in...

Full description

Saved in:
Bibliographic Details
Main Authors PATRA, Mahesh, CHOI, Sangdun, CHOI, Yang-Seon, MUHAMMAD, Haseeb
Format Patent
LanguageEnglish
French
German
Published 28.06.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to a small molecule compound inhibiting a toll-like receptor (TLR) signal transmission path and, more specifically, to a compound having a structure expressed by a particular chemical formula, a TLR inhibitory composition comprising same, and an autoimmune disease or inflammatory disease prevention or therapeutic composition comprising the TLR inhibitory composition. In the present invention, a TLR inhibitory compound TIC10, inhibiting a TLR7- and TLR9-mediated signal transmission path, and a derivative TIC10-7 thereof have been confirmed. The novel compounds block the TNF-α secretion by inhibiting the expression and activation of NF-κB- and MAPK-related proinflammatory genes, and thus can be utilized as a therapeutic agent for many autoimmune diseases, such as systemic lupus erythematosus, psoriasis and psoriatic arthritis, associated with a hyperactivity of a nucleic acid detection TLR.
Bibliography:Application Number: EP20200847286